PDSB Quote, Financials, Valuation and Earnings

Cocrystal Pharma has a net margin of -- compared to PDS Biotechnology's net margin of --. PDS Biotechnology's return on equity of -- beat Cocrystal Pharma's return on equity of --.

PDS Biotechnology has a consensus price target of $7.50, signalling upside risk potential of 447.45%. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 482.75%. Given that Cocrystal Pharma has higher upside potential than PDS Biotechnology, analysts believe Cocrystal Pharma is more attractive than PDS Biotechnology.

PDS Biotechnology has a beta of 1.397, which suggesting that the stock is 39.741% more volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.692%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than Cocrystal Pharma quarterly revenues of --. PDS Biotechnology's net income of -$8.5M is lower than Cocrystal Pharma's net income of -$2.3M. Notably, PDS Biotechnology's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus 7.22x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to PDS Biotechnology's net margin of -49.65%. PDS Biotechnology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

PDS Biotechnology has a consensus price target of $7.50, signalling upside risk potential of 447.45%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 51.11%. Given that PDS Biotechnology has higher upside potential than NovaBay Pharmaceuticals, analysts believe PDS Biotechnology is more attractive than NovaBay Pharmaceuticals.

PDS Biotechnology has a beta of 1.397, which suggesting that the stock is 39.741% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. PDS Biotechnology's net income of -$8.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, PDS Biotechnology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rafarma Pharmaceuticals has a net margin of -- compared to PDS Biotechnology's net margin of --. PDS Biotechnology's return on equity of -- beat Rafarma Pharmaceuticals's return on equity of --.

PDS Biotechnology has a consensus price target of $7.50, signalling upside risk potential of 447.45%. On the other hand Rafarma Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that PDS Biotechnology has higher upside potential than Rafarma Pharmaceuticals, analysts believe PDS Biotechnology is more attractive than Rafarma Pharmaceuticals.

PDS Biotechnology has a beta of 1.397, which suggesting that the stock is 39.741% more volatile than S&P 500. In comparison Rafarma Pharmaceuticals has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.453%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rafarma Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. Rafarma Pharmaceuticals pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than Rafarma Pharmaceuticals quarterly revenues of --. PDS Biotechnology's net income of -$8.5M is higher than Rafarma Pharmaceuticals's net income of --. Notably, PDS Biotechnology's price-to-earnings ratio is -- while Rafarma Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus -- for Rafarma Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -- compared to PDS Biotechnology's net margin of -692.84%. PDS Biotechnology's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -121.16%.

PDS Biotechnology has a consensus price target of $7.50, signalling upside risk potential of 447.45%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $60.00 which suggests that it could grow by 59.19%. Given that PDS Biotechnology has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe PDS Biotechnology is more attractive than Tonix Pharmaceuticals Holding.

PDS Biotechnology has a beta of 1.397, which suggesting that the stock is 39.741% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 1.627, suggesting its more volatile than the S&P 500 by 62.658%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.4M. PDS Biotechnology's net income of -$8.5M is higher than Tonix Pharmaceuticals Holding's net income of -$16.8M. Notably, PDS Biotechnology's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus 10.30x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.